Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 9:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vigamox Eye Drops Clear all
Completed Phase 4 Interventional

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

NCT01455233
View directory record Official record
Conditions
Corneal Health, Cataract Surgery
Interventions
besivance, vigamox
Drug
Lead sponsor
Ophthalmology Consultants, Ltd.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Results available

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

NCT00870103
View directory record Official record
Conditions
Cataract
Interventions
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional

Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

NCT00690313
View directory record Official record
Conditions
Intravitreal Injection Patients
Interventions
Vigamox
Drug
Lead sponsor
Illinois Retina Associates
Other
Eligibility
21 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Harvey, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

NCT00464438
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
gatifloxacin, moxifloxacin 0.5% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
Up to 31 Days
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Results available

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

NCT00824070
View directory record Official record
Conditions
Cataract Extraction
Interventions
Besifloxacin hydrochloride, moxifloxacin hydrochloride, gatifloxacin
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

NCT00703313
View directory record Official record
Conditions
Healthy
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Sep 10, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional Results available

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

NCT01928693
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Besivance 0.6% Ophthalmic Suspension, Zymaxid 0.5% Ophthalmic Solution, Vigamox 0.5% Ophthalmic Solution
Drug
Lead sponsor
Cornea Consultants Of Nashville
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional

Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

NCT00630019
View directory record Official record
Conditions
Cataract
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

NCT04521140
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 10, 2026, 9:49 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC

NCT06681688
View directory record Official record
Conditions
Cataract
Interventions
Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}, Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
Drug
Lead sponsor
Inder Paul Singh, M.D.
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Venice, Florida • Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Results available

Antibiotic Resistance In Eye Surgeries

NCT04750655
View directory record Official record
Conditions
Antibiotic Resistance, Ocular Surface Microbiome, Gut Resistome
Interventions
Moxifloxacin (Topical)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 10, 2026, 9:49 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

NCT00414011
View directory record Official record
Conditions
Epithelium, Corneal
Interventions
Moxifloxacin, Gatifloxacin
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

NCT00575367
View directory record Official record
Conditions
Bacterial Infections, Eye Infections
Interventions
AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

NCT00905762
View directory record Official record
Conditions
Healthy
Interventions
Gatifloxacin, Moxifloxacin, Besifloxacin
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 3 Interventional

AL-15469A for the Treatment of Bacterial Conjunctivitis

NCT00332293
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Month and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 10, 2026, 9:49 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery

NCT04205916
View directory record Official record
Conditions
Patient Preference
Interventions
Dexamethasone, Standard of care surgery
Drug · Other
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
22 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 10, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional

A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

NCT00579020
View directory record Official record
Conditions
Corneal Infiltrates
Interventions
Moxifloxacin/dexamethasone phosphate ophthalmic solution, Moxifloxacin ophthalmic solution 0.5%, Dexamethasone phosphate solution, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

NCT01296191
View directory record Official record
Conditions
Cataracts
Interventions
Moxifloxacin, besifloxacin
Drug
Lead sponsor
Frank A. Bucci, Jr., M.D.
Other
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Results available

Study of Ocular Penetration of Topically Administered Fluoroquinolones

NCT00924729
View directory record Official record
Conditions
Cataract Extraction
Interventions
Moxifloxacin 0.5% ophthalmic solution, Besifloxacin 0.6% ophthalmic suspension
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 3 Interventional

Steroids and Cross-linking for Ulcer Treatment

NCT04097730
View directory record Official record
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Results available

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

NCT00312338
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
VIGAMOX
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year to 13 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Sep 10, 2026, 9:49 AM EDT
Completed Phase 4 Interventional

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

NCT00758199
View directory record Official record
Conditions
Cataracts
Interventions
Bromfenac, Moxifloxacin hydrochloride, Prednisolone Acetate
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 10, 2026, 9:49 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose

NCT00347828
View directory record Official record
Conditions
Eye Infection, Infection
Interventions
Moxifloxacin ophthalmic solution 0.5%, Gatifloxacin ophthalmic solution 0.3%
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2006 · Synced Sep 10, 2026, 9:49 AM EDT